Additionally, co-treatment with the FABP4 inhibitor BMS309403 and cetuximab in the co-culture system of CTX-DTP CRC cells and adipocytes decreased the invasiveness of CRC persister cells, indicating that inhibiting FABP4 disrupts adipocyte-induced cetuximab tolerance in CRC cells (Fig. 6F; scale bar = 50 μm). Here, FABP4 is linked to colorectal carcinoma.